Fusion proteins of B7.1 And a carcinoembryonic antigen (CEA)-specific antibody fragment opsonize CEA-expressing tumor cells and coactivate T-cell immunity

International Journal of Cancer

Volumn 92, Issue 5, 2001, Pages 725-732

  Hoffmann, Philipp ^b   Mueller, Nicole ^c   Shively, John E ^b   Fleischer, Bernhard ^c   Neumaier, Michael ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

B7.1 costimulation; Carcinoembryonic antigen (CEA); CEACAM; T cell activation; Tumor immunity

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER ANTIBODY; CARCINOEMBRYONIC ANTIGEN; HYBRID PROTEIN; PROTEIN B7.1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL MEMBRANE; CELLULAR IMMUNITY; CHO CELL; CONTROLLED STUDY; GENETIC CODE; GENETIC ENGINEERING; HUMORAL IMMUNITY; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD80; BASE SEQUENCE; CARCINOEMBRYONIC ANTIGEN; FLOW CYTOMETRY; IMMUNOGLOBULIN FRAGMENTS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; PHAGOCYTOSIS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0035371903     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010601)92:5<725::AID-IJC1252>3.0.CO;2-S     Document Type: Article

References (53)

1. Cancer immunology: The search for specificity - G.H.A. Clowes Memorial lecture
2. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
3. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
4. Molecular characterization of a cloned idiotypic cascade containing a network antigenic determinant specific for the human carcinoembryonic antigen
5. Effect of specific antibody pretreatment on liver uptake of 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografis
6. Imaging of colon carcinoma with 111-indium-labeled anti-CEA monoclonal antibodies (Indacea) prior to surgery
7. Presurgical imaging with indium-labeled anti-carcinoembryonic antigen for colon cancer staging
8. Carcinoembryonic antigen expression of resurgent human colon carcinoma after treatment with therapeutic doses of 90Y-alpha-carcinoembryonic antigen monoclonal antibody
9. Estimation of monoclonal antibody-associated 90Y activity needed to achieve certain tumor radiation doses in colorectal cancer patients
10. Tumor uptake as a function of tumor mass: A mathematic model
11. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients
12. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody
13. Initial experience evaluating 90yttrium-radio-labeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial
14. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers
15. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
16. Adoptive T-cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
17. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes
18. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours
19. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors
20. Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation
21. Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I
22. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
23. Costimulatory signals through B7.1/CD28 prevent T-cell apoptosis during targeT-cell lysis
24. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro
25. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help
26. Comparative analysis of B7-1 and B7-2 costimulatory ligands: Expression and function
27. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules
28. Tumor immunogenicity determines the effect of B7 costimulation on T-cell-mediated tumor immunity
29. Tumor rejection after direct costimulation of CD8+ T-cells by B7-transfected melanoma cells
30. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization
31. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T-cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct
32. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension
33. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli
34. A monoclonal anti-idiotypic antibody bearing the image of an epitope specific to the human carcinoembryonic antigen
35. Costimulation of T-cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene
36. Immunogenicity of retransplanted rat kidney allografts. Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient
37. The role of accessory cells in polyclonal T-cell activation. III. No requirement for recognition of H-2-encoded antigens on accessory cells
38. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells
39. Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells
40. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells
41. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T-cell costimulatory pathway
42. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins
43. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML
44. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules
45. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
46. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model
47. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules
48. CEA-related antigens: Molecular biology and clinical significance
49. Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs
50. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain
51. "Diabodies": Small bivalent and bispecific antibody fragments
52. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody
53. Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment